Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes
Key facts
- Who runs it
- University Hospital, Strasbourg, France
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 4
- People taking part
- 38 people enrolled
- Started
- 17 Aug 2020
- Ended
- 20 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)
- F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)
- Record updated
- 5 March 2025
- Why it stopped
- Difficulties of inclusion in this rare pathology
Who can take part
- Age
- 10 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Patient with cystic fibrosis related diabetes aged over 10 years (no upper age limite)
- Patient treated by multiple insulin injections (minimal three insulin injections per day or basal bolus insulin regimen) or insulin pump
- Patient with CGM from over 3 months (at the signature of the study's informed consent) or patient not wearing a CGM device, but agreeing a CGM at the inclusion and at the end of each treatment period of 3 months
- Naive patient of Fiasp or patient under Fiasp, having carried out a run-in period of one month with rapid acting insulin treatment
- Affiliated to a social security scheme
- Subject able to understand the objectives and the risks related to the research and to give a dated and signed informed consent
- Subject having been informed of the results of the prior medical examination
- Written informed consent, dated and signed before initiating any trial-related procedure (if the subject is a minor, the consent must be signed by the 2 legal representative and the patient if he/she is able to give consent)
Who cannot take part
- Patient with cystic fibrosis related diabetes treated with 2 injections / day
- Patient on lung transplant waiting list or transplanted within one year prior to the inclusion visit
- Patient who started treatment with Trikafta® within 3 months prior to the inclusion visit
- Subject in exclusion period (determined by previous or current clinical study)
- Patient with type 1 or type 2 diabetes
- Impossibility of giving the subject enlightened information (subject in emergency situation, difficulties of understanding, cognitive impairment...)
- Patient with an HbA1C greater than 12% who demonstrate therapeutic non-compliance
- Patient pregnant (positive urinary pregnancy test) or wishing to pregnancy
- Contraindication to Aspart insulin
- Patient who cannot be followed during 12 months
- Subject under the protection of justice
- Subject under guardianship or curatorship
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Cystic fibrosis related diabetes (CFRD) is a major factor of morbidity and mortality at all disease stages. Insulin deficiency has serious clinical consequences by increasing malnutrition, since protein and lipid catabolism is accelerated in chronic infections. Traditionally, insulin is injected before a meal. Yet, in these patients with highly varied and often staggered nutritional intakes, insulin injection can result in an increased risk of postprandial hypoglycaemia, all the more so as CF patients exhibit decreased glucagon secretion.
Read full original descriptionShow less
Recent progress in the development of new insulins mimicking the physiological secretion more closely has led to ultra-fast insulins (fast aspart), allowing for postprandial hyperglycaemia to be better controlled. In Type 1 diabetics treated with basal-bolus, faster-acting aspart insulin injected after a meal enabled metabolic control comparable to injection of aspart insulin prior to the meal. Fast apart insulin is of particular interest with regard to CFRD, wherein postprandial hyperglycaemia occurs early. In CFRD, these insulins are likewise advantageous in that they can be injected after the meal, thus permitting more flexibility in patients with highly varied diets. Moreover, the insulin dose can be adapted depending on dietary intake, thus preventing hypoglycaemia secondary to highly-varied carbohydrate intakes. Due to its flexibility, this insulin therapy is likely to be better accepted by patients with cystic fibrosis.
The 2 groups in the trial
- Group 1: A-F-A-FExisting treatment, for comparison
The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study. All patients will test both insulin treatments (A and F) in alternating periods. The patients of group 1 will start with pre-prandial aspart insulin (NovoRapid). Each treatment period will last 3 months.
Treatment: A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)
- Groupe 2: F-A-F-AExisting treatment, for comparison
The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study. All patients will test both insulin treatments (A and F) in alternating periods. The patients of group 2 will start with post prandial Faster-acting aspart insulin (FIASP).
Treatment: F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes : MIRE Trial
- Record updated
- 5 March 2025